Enhanced Lymphatic Uptake of Leflunomide Loaded Nanolipid Carrier via Chylomicron Formation for the Treatment of Rheumatoid Arthritis

Yadhu Krishnan ¹, Shilpa Mukundan ¹, Suresh Akhil ¹, Swati Gupta ¹, Vidya Viswanad ¹ *

Cited by CrossRef: 18

1- Obinu A, Burrai G, Cavalli R, Galleri G, Migheli R, Antuofermo E, Rassu G, Gavini E, Giunchedi P. Transmucosal Solid Lipid Nanoparticles to Improve Genistein Absorption via Intestinal Lymphatic Transport. Pharmaceutics. 2021;13(2):267 [Crossref]

2- Zewail M, Doghish A, El-Husseiny H, Mady E, Mohammed O, Elbadry A, Elbokhomy A, Bhnsawy A, El-Dakroury W. Lipid-based nanocarriers: an attractive approach for rheumatoid arthritis management. Biomater Sci. 2024;12(24):6163 [Crossref]

3- Rodrigues da Silva G, Lemes J, Geronimo G, Freitas de Lima F, de Moura L, Carvalho dos Santos A, Carvalho N, Malange K, Breitkreitz M, Parada C, de Paula E. Lipid nanoparticles loaded with butamben and designed to improve anesthesia at inflamed tissues. Biomater Sci. 2021;9(9):3378 [Crossref]

4- Zhu Y, Zhao T, Liu M, Wang S, Liu S, Yang Y, Yang Y, Nan Y, Huang Q, Ai K. Rheumatoid arthritis microenvironment insights into treatment effect of nanomaterials. Nano Today. 2022;42:101358 [Crossref]

5- Shah S, Rangaraj N, Singh S, Srivastava S. Exploring the unexplored avenues of surface charge in nano-medicine. Colloid and Interface Science Communications. 2021;42:100406 [Crossref]

6- Singh S, Tiwary N, Sharma N, Behl T, Antil A, Anwer M, Ramniwas S, Sachdeva M, Elossaily G, Gulati M, Ohja S. Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management. Pharmaceuticals. 2024;17(2):248 [Crossref]

7- Chaturvedi S, Garg A, Verma A. Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: An insight into the in-vitro, ex-vivo, in-situ and in-vivo study models. Journal of Drug Delivery Science and Technology. 2020;59:101899 [Crossref]

8- Amekyeh H, Sabra R, Billa N. A Window for Enhanced Oral Delivery of Therapeutics via Lipid Nanoparticles. DDDT. 2024;Volume 18:613 [Crossref]

9- Blei F. Update October 2018. Lymphatic Research and Biology. 2018;16(5):471 [Crossref]

10- Li Y, Qi W. Experimental Study of Nanostructured Lipid Carrier in the Treatment of Immune Lupus Nephritis. j nanosci nanotechnol. 2021;21(2):1099 [Crossref]

11- Zewail M, Nafee N, Boraie N. Intra-Articular Dual Drug Delivery for Synergistic Rheumatoid Arthritis Treatment. Journal of Pharmaceutical Sciences. 2021;110(7):2808 [Crossref]

12- Thampi L, E J G. In-vitro and In-vivo Characterization of Anti-Onychomycotic Transungual patches - A Systematic Review. RJPT. 2023;:1527 [Crossref]

13- Zhang Z, Lu Y, Qi J, Wu W. An update on oral drug delivery via intestinal lymphatic transport. Acta Pharmaceutica Sinica B. 2021;11(8):2449 [Crossref]

14- Alhelal H, Mehta S, Kadian V, Kakkar V, Tanwar H, Rao R, Aldhubiab B, Sreeharsha N, Shinu P, Nair A. Solid Lipid Nanoparticles Embedded Hydrogels as a Promising Carrier for Retarding Irritation of Leflunomide. Gels. 2023;9(7):576 [Crossref]

15- Yan S, Cheng Y, Li L, Zhong C, Chen C, Gao X. Lipid-based formulations: A promising approach for poorly soluble drug delivery via the intestinal lymphatic system. Journal of Drug Delivery Science and Technology. 2023;87:104770 [Crossref]

16- Zewail M, Nafee N, Helmy M, Boraie N. Coated nanostructured lipid carriers targeting the joints – An effective and safe approach for the oral management of rheumatoid arthritis. International Journal of Pharmaceutics. 2019;567:118447 [Crossref]

17- Anita C, Munira M, Mural Q, Shaily L. Topical nanocarriers for management of Rheumatoid Arthritis: A review. Biomedicine & Pharmacotherapy. 2021;141:111880 [Crossref]

18- Zewail M. Leflunomide nanocarriers: a new prospect of therapeutic applications. Journal of Microencapsulation. 2024;41(8):715 [Crossref]